dc.contributor.author | Shiraz, A | |
dc.contributor.author | Egawa, N | |
dc.contributor.author | Pelt, DM | |
dc.contributor.author | Crawford, R | |
dc.contributor.author | Nicholas, AK | |
dc.contributor.author | Romashova, V | |
dc.contributor.author | Sasieni, P | |
dc.contributor.author | Griffin, H | |
dc.contributor.author | Doorbar, J | |
dc.date.accessioned | 2024-05-13T10:56:35Z | |
dc.date.available | 2022-06-28 | |
dc.date.available | 2024-05-13T10:56:35Z | |
dc.date.issued | 2022-07-18 | |
dc.identifier.citation | Aslam Shiraz, Nagayasu Egawa, Daniël M. Pelt, Robin Crawford, Adeline K. Nicholas, Veronika Romashova, Peter Sasieni, Heather Griffin, John Doorbar, Cervical cell lift: A novel triage method for the spatial mapping and grading of precancerous cervical lesions, eBioMedicine, Volume 82, 2022, 104157, ISSN 2352-3964, https://doi.org/10.1016/j.ebiom.2022.104157. (https://www.sciencedirect.com/science/article/pii/S2352396422003383) Abstract: Summary Background Primary HPV screening, due to its low specificity, requires an additional liquid-based cytology (LBC) triage test. However, even with LBC triage there has been a near doubling in the number of patients referred for colposcopy in recent years, the majority having low-grade disease. Methods To counter this, a triage test that generates a spatial map of the cervical surface at a molecular level has been developed which removes the subjectivity associated with LBC by facilitating identification of lesions in their entirety. 50 patients attending colposcopy were recruited to participate in a pilot study to evaluate the test. For each patient, cells were lifted from the cervix onto a membrane (cervical cell lift, CCL) and immunostained with a biomarker of precancerous cells, generating molecular maps of the cervical surface. These maps were analysed to detect high-grade lesions, and the results compared to the final histological diagnosis. Findings We demonstrated that spatial molecular mapping of the cervix has a sensitivity of 90% (95% CI 69-98) (positive predictive value 81% (95% CI 60-92)) for the detection of high-grade disease, and that AI-based analysis could aid disease detection through automated flagging of biomarker-positive cells. Interpretation Spatial molecular mapping of the CCL improved the rate of detection of high-grade disease in comparison to LBC, suggesting that this method has the potential to decisively identify patients with clinically relevant disease that requires excisional treatment. Funding CRUK Early Detection Project award, Jordan-Singer BSCCP award, Addenbrooke's Charitable Trust, UK-MRC, Janssen Pharmaceuticals/Advanced Sterilisation Products, and NWO. Keywords: Methodology for cervical screening; Cervical cancer; Triage test; HPV; Biomarker for cervical screening; Spatial mapping of lesion; Non-invasive sampling; Cytology; CIN | en_US |
dc.identifier.issn | 2352-3964 | |
dc.identifier.other | ARTN 104157 | |
dc.identifier.other | ARTN 104157 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/96819 | |
dc.description.abstract | Background
Primary HPV screening, due to its low specificity, requires an additional liquid-based cytology (LBC) triage test. However, even with LBC triage there has been a near doubling in the number of patients referred for colposcopy in recent years, the majority having low-grade disease.
Methods
To counter this, a triage test that generates a spatial map of the cervical surface at a molecular level has been developed which removes the subjectivity associated with LBC by facilitating identification of lesions in their entirety. 50 patients attending colposcopy were recruited to participate in a pilot study to evaluate the test. For each patient, cells were lifted from the cervix onto a membrane (cervical cell lift, CCL) and immunostained with a biomarker of precancerous cells, generating molecular maps of the cervical surface. These maps were analysed to detect high-grade lesions, and the results compared to the final histological diagnosis.
Findings
We demonstrated that spatial molecular mapping of the cervix has a sensitivity of 90% (95% CI 69-98) (positive predictive value 81% (95% CI 60-92)) for the detection of high-grade disease, and that AI-based analysis could aid disease detection through automated flagging of biomarker-positive cells.
Interpretation
Spatial molecular mapping of the CCL improved the rate of detection of high-grade disease in comparison to LBC, suggesting that this method has the potential to decisively identify patients with clinically relevant disease that requires excisional treatment. | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.ispartof | EBIOMEDICINE | |
dc.rights | This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/) | |
dc.subject | Methodology for cervical screening | en_US |
dc.subject | Cervical cancer | en_US |
dc.subject | Triage test | en_US |
dc.subject | HPV | en_US |
dc.subject | Biomarker for cervical screening | en_US |
dc.subject | Spatial mapping of lesion | en_US |
dc.subject | Non-invasive sampling | en_US |
dc.subject | Cytology | en_US |
dc.subject | CIN | en_US |
dc.title | Cervical cell lift: A novel triage method for the spatial mapping and grading of precancerous cervical lesions | en_US |
dc.type | Article | en_US |
dc.rights.holder | © 2022 Published by Elsevier B.V. | |
dc.identifier.doi | 10.1016/j.ebiom.2022.104157 | |
pubs.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000830983200004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 82 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |